Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those with previous adverse reactions.

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical investors.

The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S. regulators ordering an end to the practice.

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, while operating profit expands 10% to 16%, based on constant exchange rates.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health risks; buy from trusted sources.

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | A federal district court in Delaware has taken the side of Mylan—now part of Viatris—in a patent litigation case over a proposed generic to Novo Nordisk's obesity blockbuster Wegovy.